Breaking News Instant updates and real-time market news.

DVAX

Dynavax

$10.82

0.05 (0.46%)

, MRK

Merck

$62.77

0.11 (0.18%)

17:24
10/09/16
10/09
17:24
10/09/16
17:24

Dynavax reports Phase 1/2 data on SD-101

Dynavax Technologies (DVAX) announced the first presentation of findings from an ongoing Phase 1/2 study evaluating SD-101 in combination with Keytruda, Merck's (MRK) anti-PD-1 treatment. Early results evaluating five patients with metastatic melanoma for efficacy and 16 patients for safety were reported. In patients naive to anti-PD-1 treatment objective responses were observed in three out of four, including one complete response and two partial responses. One patient with progressive disease while receiving anti-PD-1 therapy was observed to have stable disease. SD-101 in combination with pembrolizumab was well-tolerated. No dose-limiting toxicities of the combination were observed in any dose cohort, and a maximum tolerated dose was not identified. No immune-related adverse events were reported, and the most common treatment-emergent adverse events were grade 1-2 flu-like symptoms, including fever, chills and myalgia consistent with the engagement of TLR9 and production of interferon alpha. The study also included biomarker assessments suggesting that treatment with SD-101 and pembrolizumab resulted in elevation of gene signatures consistent with an increase in immune cell types and multiple immune functions.

DVAX

Dynavax

$10.82

0.05 (0.46%)

MRK

Merck

$62.77

0.11 (0.18%)

  • 25

    Oct

  • 06

    Nov

  • 16

    Nov

  • 15

    Dec

DVAX Dynavax
$10.82

0.05 (0.46%)

04/27/16
COWN
04/27/16
NO CHANGE
Target $60
COWN
Outperform
Dynavax PDUFA extension will not impact approval chances, says Cowen
Cowen analyst Phil Nadeau does not beleive Dynavax's Heplisav PDUFA extension by 3 months will impact chances of approval. The analyst suspects that the PDUFA change has more to do with FDA managing its workload than any reflection on the substance of the BLA, since both the FDA and Dynavax had agreed upon the original format of the BLA resubmission. Nadeau continues to rate Dynavax an Outperform and top small cap pick with a $60 price target on shares.
04/27/16
RBCM
04/27/16
DOWNGRADE
RBCM
Sector Perform
Dynavax downgraded to Sector Perform from Outperform at RBC Capital
04/28/16
RBCM
04/28/16
DOWNGRADE
RBCM
Sector Perform
Dynavax downgraded on drug safety concerns at RBC Capital
As noted earlier, RBC Capital downgraded Dynavax to Sector Perform from Outperform, The firm cited concerns about the safety of the company's Heplisav-B drug as the reason for its downgrade. RBC says that the FDA's decision to request individual trial data instead of the integrated dataset shows that the agency's scrutiny of the drug's safety has increased. Target to $17 from $48.
09/06/16
WBLR
09/06/16
NO CHANGE
WBLR
Outperform
FDA panel cancelation positive for Dynavax, says William Blair
William Blair analyst Y. Katherine Xu views the FDA's decision to canceled the November 16 Vaccines and Related Biological Products Advisory Committee meeting for Heplisav as a net positive for Dynavax. The agency's decision to move straight to the PDUFA date suggests that the Heplisav package is "sufficiently strong and adequate to warrant approval in the absence of a panel," Xu tells investors in a research note. She keeps an Outperform rating on Dynavax. The stock is up 19% to $13.00 in pre-market trading.
MRK Merck
$62.77

0.11 (0.18%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.

TODAY'S FREE FLY STORIES

S

Sprint

$9.29

0.02 (0.22%)

09:00
02/23/17
02/23
09:00
02/23/17
09:00
Hot Stocks
Sprint, Open Mobile announce JV in Puerto Rico, U.S. Virgin Islands »

Sprint and PR Wireless,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 06

    Mar

SFTBF

SoftBank

$76.90

-0.3575 (-0.46%)

, VOD

Vodafone

09:00
02/23/17
02/23
09:00
02/23/17
09:00
Periodicals
SoftBank denies looking for stake in Vodafone Indian unit, Bloomberg reports »

SoftBank (SFTBF) has…

SFTBF

SoftBank

$76.90

-0.3575 (-0.46%)

VOD

Vodafone

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:00
02/23/17
02/23
09:00
02/23/17
09:00
General news
FX Action: The dollar »

FX Action: The dollar…

SSD

Simpson Manufacturing

$44.24

-0.62 (-1.38%)

08:59
02/23/17
02/23
08:59
02/23/17
08:59
Hot Stocks
Simpson Manufacturing to adopt proxy access bylaws amendment »

Simpson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSS

Kohl's

08:57
02/23/17
02/23
08:57
02/23/17
08:57
Hot Stocks
Kohl's says has 'nothing specific in mind' on M&A »

Says company in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 19

    Mar

AGN

Allergan

$246.32

-0.84 (-0.34%)

08:56
02/23/17
02/23
08:56
02/23/17
08:56
Periodicals
Allergan CEO proposes Trump lead drug price negotiations, Bloomberg reports »

Allergan CEO Brent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 04

    May

BAC

Bank of America

$24.79

0.01 (0.04%)

, TSLA

Tesla

$273.51

-3.88 (-1.40%)

08:56
02/23/17
02/23
08:56
02/23/17
08:56
Options
Notable open interest changes for February 23rd »

Wednesday's total…

BAC

Bank of America

$24.79

0.01 (0.04%)

TSLA

Tesla

$273.51

-3.88 (-1.40%)

JCP

J.C. Penney

$7.05

-0.01 (-0.14%)

FB

Facebook

$136.12

2.4 (1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 24

    Feb

  • 28

    Feb

  • 28

    Feb

  • 06

    Mar

  • 19

    Mar

  • 28

    Mar

TNC

Tennant

$70.10

-1.9 (-2.64%)

08:55
02/23/17
02/23
08:55
02/23/17
08:55
Hot Stocks
Breaking Hot Stocks news story on Tennant 

Tennant trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SFTBF

SoftBank

$76.90

-0.3575 (-0.46%)

, VOD

Vodafone

08:55
02/23/17
02/23
08:55
02/23/17
08:55
Periodicals
SoftBank in talks to buy stake in Vodafone Indian unit, The Economic Times says »

Softbank (SFTBF) could…

SFTBF

SoftBank

$76.90

-0.3575 (-0.46%)

VOD

Vodafone

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:55
02/23/17
02/23
08:55
02/23/17
08:55
General news
The 6k U.S. initial claims rise to 244k »

The 6k U.S. initial…

THG

Hanover Insurance

$91.08

0.43 (0.47%)

08:55
02/23/17
02/23
08:55
02/23/17
08:55
Conference/Events
Hanover Insurance to host investor day »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 05

    Mar

HNR

Harvest Natural

$6.68

0.04 (0.60%)

08:55
02/23/17
02/23
08:55
02/23/17
08:55
Conference/Events
Harvest Natural to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

TNC

Tennant

$70.10

-1.9 (-2.64%)

08:54
02/23/17
02/23
08:54
02/23/17
08:54
Hot Stocks
Tennant to reduce 3% of global workforce »

Tennant announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

TNC

Tennant

$70.10

-1.9 (-2.64%)

08:53
02/23/17
02/23
08:53
02/23/17
08:53
Earnings
Tennant sees 2017 adjusted EPS $2.50-$2.70, consensus $2.83 »

On an as adjusted and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

STNG

Scorpio Tankers

$4.28

-0.01 (-0.23%)

08:53
02/23/17
02/23
08:53
02/23/17
08:53
Upgrade
Scorpio Tankers rating change  »

Scorpio Tankers upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

KSS

Kohl's

08:52
02/23/17
02/23
08:52
02/23/17
08:52
Hot Stocks
Kohl's sees significant improvement in Q1 gross margin »

Sees significant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 19

    Mar

TNC

Tennant

$70.10

-1.9 (-2.64%)

08:51
02/23/17
02/23
08:51
02/23/17
08:51
Earnings
Tennant reports Q4 EPS 85c, consensus 76c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

LMRK

Landmark Infrastructure

08:50
02/23/17
02/23
08:50
02/23/17
08:50
Syndicate
Breaking Syndicate news story on Landmark Infrastructure »

Landmark Infrastructure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

KSS

Kohl's

, UA

Under Armour

$19.78

0.09 (0.46%)

08:50
02/23/17
02/23
08:50
02/23/17
08:50
Hot Stocks
Kohl's CEO believes uncertainty in sector will continue »

Kohl's (KSS) says…

KSS

Kohl's

UA

Under Armour

$19.78

0.09 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 19

    Mar

ABBV

AbbVie

$61.36

-0.47 (-0.76%)

, AGN

Allergan

$246.32

-0.84 (-0.34%)

08:50
02/23/17
02/23
08:50
02/23/17
08:50
Conference/Events
Piper Jaffray healthcare/pharma analyst holds analyst/industry conference call »

Analyst Schimmer, along…

ABBV

AbbVie

$61.36

-0.47 (-0.76%)

AGN

Allergan

$246.32

-0.84 (-0.34%)

BMY

Bristol-Myers

$55.35

0.57 (1.04%)

ENTA

Enanta

$28.18

-0.36 (-1.26%)

GALT

Galectin Therapeutics

$1.71

-0.23 (-11.86%)

GILD

Gilead

$68.83

-0.46 (-0.66%)

GLMD

Galmed

$4.09

-0.16 (-3.76%)

ICPT

Intercept

$122.79

-2.66 (-2.12%)

MRK

Merck

$65.29

-0.19 (-0.29%)

RGLS

Regulus

$1.08

-0.025 (-2.27%)

VKTX

Viking Therapeutics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Feb

  • 02

    Mar

  • 06

    Mar

  • 06

    Mar

  • 08

    Mar

  • 09

    Mar

  • 15

    Mar

  • 17

    Mar

  • 01

    Apr

  • 04

    May

  • 10

    May

  • 27

    May

  • 14

    Jun

08:50
02/23/17
02/23
08:50
02/23/17
08:50
General news
Atlanta Fed centrist Lockhart sees the pendulum swinging »

Atlanta Fed centrist…

W

Wayfair

$41.26

1 (2.48%)

08:49
02/23/17
02/23
08:49
02/23/17
08:49
Hot Stocks
Breaking Hot Stocks news story on Wayfair »

Wayfair down 10.3% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

TWX

Time Warner

$96.32

-0.1 (-0.10%)

, T

AT&T

$41.59

-0.14 (-0.34%)

08:46
02/23/17
02/23
08:46
02/23/17
08:46
Periodicals
Time Warner IR head to lead AT&T integration, THR reports »

Time Warner (TWX) head of…

TWX

Time Warner

$96.32

-0.1 (-0.10%)

T

AT&T

$41.59

-0.14 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 06

    Mar

QQQ

NASDAQ 100 Index Tracking Stock

$130.50

0.05 (0.04%)

, ETE

Energy Transfer Equity

$18.92

-0.13 (-0.68%)

08:46
02/23/17
02/23
08:46
02/23/17
08:46
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

QQQ

NASDAQ 100 Index Tracking Stock

$130.50

0.05 (0.04%)

ETE

Energy Transfer Equity

$18.92

-0.13 (-0.68%)

FIT

Fitbit

$5.88

-0.16 (-2.65%)

NAK

Northern Dynasty

$1.39

-0.27 (-16.27%)

BX

Blackstone

$30.32

-0.23 (-0.75%)

PCLN

Priceline

$1,651.74

4.74 (0.29%)

TBT

ProShares UltraShort 20+ yr Trsry

$39.71

-0.14 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Feb

  • 28

    Feb

TNC

Tennant

$70.10

-1.9 (-2.64%)

08:45
02/23/17
02/23
08:45
02/23/17
08:45
Hot Stocks
Tennant announces agreement with Ambienta to acquire IPC Group for $350M »

Tennant Company announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.